sNDA Submitted: Spravato as Monotherapy for Treatment-Resistant Depression – Psychiatric Times July 25, 2024 Medicine sNDA Submitted: Spravato as Monotherapy for Treatment-Resistant Depression Psychiatric Times J&J seeks expanded approval for antidepressant Spravato BioPharma Dive Johnson & Johnson says its ketamine-based drug can treat depression Quartz Johnson & Johnson seeks FDA nod for depression nasal… Source link
July 25, 2024 Medicine sNDA Submitted: Spravato as Monotherapy for Treatment-Resistant Depression Psychiatric Times J&J seeks expanded approval for antidepressant Spravato BioPharma Dive Johnson & Johnson says its ketamine-based drug can treat depression Quartz Johnson & Johnson seeks FDA nod for depression nasal… Source link